Registered outcomes13

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 13 of 13

Download this page as JSON

List	Outcome	Time frame	Description
Primary	Determine the progression-free survival (PFS) of mezigdomide, carfilzomib and dexamethasone (480Kd) in participants with relapsed or refractory multiple myeloma (RRMM)	2 years	PFS defined as the time from inclusion to first documentation of progressive disease (PD) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma or death due to any cause, whichever occurs first.
Secondary	Overall Survival (OS)	At 2-years	Defined as the time from inclusion to time of death due to any cause
Secondary	Best overall Response Rate (ORR)	2 years	Defined as the percentage of participants who achieve best response of partial response (PR) or better according to the IMWG Uniform Response Criteria for Multiple Myeloma
Secondary	Rate of very good partial response (VGPR) or better (VGPRR)	2 years	Defined as the percentage of participants who achieve best response of VGPR or better according to the IMWG Uniform Response Criteria for Multiple Myeloma
Secondary	Rate of complete response (CR) or better (CRR)	2 years	Defined as the percentage of participants who achieve best response of CR or better according to the IMWG Uniform Response Criteria for Multiple Myeloma
Secondary	Time to Response (TTR)	2 years	Defined as the time from inclusion on to the first documentation of response (PR or better)
Secondary	Duration of Response (DOR)	2 years	Defined as the time from the first documentation of response (PR or better) to the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first
Secondary	Time to Progression (TTP)	2 years	Defined as the time from inclusion to the first documentation of PD
Secondary	Time to Next Treatment (TTNT)	2 years	Defined as the time from inclusion to the start of the next anti-myeloma treatment
Secondary	To evaluate minimal residual disease (MRD) negativity rate in participants treated with 480Kd	2 years	the proportion of participants who achieve CR or better and are MRD negative (defined at a sensitivity of a minimum of 1 in 105 nucleated cells)
Secondary	To evaluate safety of 480Kd in participants with RRMM	2 years	Defined as the type, frequency, seriousness and severity of adverse events (AEs), and relationship of AEs to study treatment
Secondary	To evaluate cancer and multiple myeloma-related symptoms	2 years	Using the European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30) and the European Quality of Life Multiple Myeloma module (EORTC QLQ-MY20) in participants treated with 480Kd
Secondary	To evaluate health-related quality of life (HRQoL)	2 years	Using HRQoL questionnaire

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07348393/registered

API reference For AI assistants